Juvenile Diabetes – References

Andrew P. Koutnik

Current: Principal Investigator & Research Faculty Institute for Sports Science and Medicine Department of Health, Nutrition, and Food Sciences College of Education, Health, and Human Sciences Florida State University; Visiting Research Scientist Human Healthspan, Resilience, and Performance Florida Institute for Human and Machine Cognition

Past: Principal Investigator, Research Scientist, Samsun Diabetes Research Institute, Principal Investigator, Research Scientist, Human Healthspan, Resilience and Performance, Florida Institute for Human and Machine Cognition, Presidential Fellow, University of South Florida Morsani College of Medicine, Department of Molecular Pharmacology & Physiology, Honor Medallion and Bess Ward Honor Awardee, Florida State University; Department of Biomedical Sciences, College of Medicine; Department of Exercise Science, College of Health and Human Sciences, Affiliate, Help a Diabetes Help a Diabetic Child. Research and Therapeutic Outreach.

Dr. Andrew P. Koutnik, Ph.D. is an award-winning research scientist recognized for his leadership in diabetes and chronic disease research

References

Juvenile Diabetes – References

  1. Collaboration NCDRF. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet 2024; 404(10467): 2077-93.
  2. Inoue K, Liu M, Aggarwal R, Marinacci LX, Wadhera RK. Prevalence and Control of Diabetes Among US Adults, 2013 to 2023. JAMA 2025.
  3. Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol 2022; 10(10): 741-60.
  4. Guo Y, Bian J, Chen A, et al. Incidence Trends of New-Onset Diabetes in Children and Adolescents Before and During the COVID-19 Pandemic: Findings from Florida. Diabetes 2022.
  5. Kendall EK, Olaker VR, Kaelber DC, Xu R, Davis PB. Association of SARS-CoV-2 Infection With New-Onset Type 1 Diabetes Among Pediatric Patients From 2020 to 2021. JAMA Netw Open 2022; 5(9): e2233014.
  6. Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther 2019; 21(2): 66-72.
  7. Lennerz BS, Koutnik AP, Azova S, Wolfsdorf JI, Ludwig DS. Carbohydrate restriction for diabetes: rediscovering centuries-old wisdom. J Clin Invest 2021; 131(1).
  8. Marzelli MJ, Mazaika PK, Barnea-Goraly N, et al. Neuroanatomical correlates of dysglycemia in young children with type 1 diabetes. Diabetes 2014; 63(1): 343-53.
  9. Barnea-Goraly N, Raman M, Mazaika P, et al. Alterations in white matter structure in young children with type 1 diabetes. Diabetes Care 2014; 37(2): 332-40.
  10. Tonoli C, Heyman E, Roelands B, et al. Type 1 diabetes-associated cognitive decline: a meta-analysis and update of the current literature. J Diabetes 2014; 6(6): 499-513.
  11. Gaudieri PA, Chen R, Greer TF, Holmes CS. Cognitive function in children with type 1 diabetes: a meta-analysis. Diabetes Care 2008; 31(9): 1892-7.
  12. Buchberger B, Huppertz H, Krabbe L, Lux B, Mattivi JT, Siafarikas A. Symptoms of depression and anxiety in youth with type 1 diabetes: A systematic review and meta-analysis. Psychoneuroendocrinology 2016; 70: 70-84.
  13. Xiang AH, Martinez MP, Chow T, et al. Depression and Anxiety Among US Children and Young Adults. JAMA Netw Open 2024; 7(10): e2436906.
  14. Hill RM, Gallagher KAS, Eshtehardi SS, Uysal S, Hilliard ME. Suicide Risk in Youth and Young Adults with Type 1 Diabetes: a Review of the Literature and Clinical Recommendations for Prevention. Curr Diab Rep 2021; 21(12): 51.
  15. Jenkins A, Januszewski A, O’Neal D. The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it. Cardiovasc Endocrinol Metab 2019; 8(1): 14-27.
  16. Dorman JS, Laporte RE, Kuller LH, et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes 1984; 33(3): 271-6.
  17. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003; 46(6): 760-5.
  18. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991; 81(9): 1158-62.
  19. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008; 115(11): 1859-68.
  20. Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017; 40(3): 412-8.
  21. Hietala K, Harjutsalo V, Forsblom C, Summanen P, Groop PH, FinnDiane Study G. Age at onset and the risk of proliferative retinopathy in type 1 diabetes. Diabetes Care 2010; 33(6): 1315-9.
  22. Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 2015; 313(1): 37-44.
  23. Conway BN, Lopes-Virella MF, Blot WJ. Late adulthood mortality among African-American and white American people with Type 1 diabetes according to age at diabetes diagnosis. Diabet Med 2018; 35(6): 729-36.
  24. Vinik A, Casellini C, Nevoret ML. Diabetic Neuropathies. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. South Dartmouth (MA); 2000.
  25. Rawshani A, Sattar N, Franzen S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 2018; 392(10146): 477-86.
  26. Livingstone SJ, Looker HC, Hothersall EJ, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 2012; 9(10): e1001321.
  27. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 2006; 29(4): 798-804.
  28. Carstensen B, Read SH, Friis S, et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia 2016; 59(5): 980-8.
  29. Songer TJ, Dorsey RR. High risk characteristics for motor vehicle crashes in persons with diabetes by age. Annu Proc Assoc Adv Automot Med 2006; 50: 335-51.
  30. Kennedy RL, Henry J, Chapman AJ, Nayar R, Grant P, Morris AD. Accidents in patients with insulin-treated diabetes: increased risk of low-impact falls but not motor vehicle crashes–a prospective register-based study. J Trauma 2002; 52(4): 660-6.
  31. R.A. W, G. B, C.P. Q, J.Y. L, J. KA, M B. Type 1 diabetes and risk of dementia in late life: The kaiser diabetes & cognitive aging study.  Alzheimers and Dementia; 2015.
  32. Simonsen JR, Harjutsalo V, Jarvinen A, et al. Bacterial infections in patients with type 1 diabetes: a 14-year follow-up study. BMJ Open Diabetes Res Care 2015; 3(1): e000067.
  33. Sarkar S, Balhara YP. Diabetes mellitus and suicide. Indian J Endocrinol Metab 2014; 18(4): 468-74.
  34. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014; 371(21): 1972-82.
  35. Mahase E. Type 1 diabetes: Global prevalence is set to double by 2040, study estimates. BMJ 2022; 378: o2289.
  36. Diabetes C, Complications Trial /Epidemiology of Diabetes I, Complications Study Research G. Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population. Diabetes Care 2016; 39(8): 1378-83.
  37. Diabetes C, Complications Trial /Epidemiology of Diabetes I, Complications Study Research G. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care 2016; 39(5): 686-93.
  38. Diabetes C, Complications Trial/Epidemiology of Diabetes I, Complications Research G. Risk Factors for Cardiovascular Disease in Type 1 Diabetes. Diabetes 2016; 65(5): 1370-9.
  39. Nordwall M, Abrahamsson M, Dhir M, Fredrikson M, Ludvigsson J, Arnqvist HJ. Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden). Diabetes Care 2015; 38(2): 308-15.
  40. Lind M, Pivodic A, Svensson AM, Olafsdottir AF, Wedel H, Ludvigsson J. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ 2019; 366: l4894.
  41. Stahl CH, Lind M, Svensson AM, Gudbjornsdottir S, Martensson A, Rosengren A. Glycaemic control and excess risk of ischaemic and haemorrhagic stroke in patients with type 1 diabetes: a cohort study of 33 453 patients. J Intern Med 2017; 281(3): 261-72.
  42. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-89.
  43. Diabetes C, Complications Trial Research G, Nathan DM, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977-86.
  44. Nathan DM, Bayless M, Cleary P, et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes 2013; 62(12): 3976-86.
  45. Nathan DM, Group DER. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014; 37(1): 9-16.
  46. Ebekozien O, Mungmode A, Sanchez J, et al. Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016-2022) from the T1D Exchange Quality Improvement Collaborative. Diabetes Technol Ther 2023; 25(11): 765-73.
  47. Watso JC, Robinson AT, Singar SAB, Cuba JN, Koutnik AP. Advanced Cardiovascular Physiology in an Individual with Type 1 Diabetes After 10-Year Ketogenic Diet. Am J Physiol Cell Physiol 2024.
  48. Koutnik AP, Klein S, Robinson AT, Watso JC. Efficacy and Safety of Long-term Ketogenic Diet Therapy in a Patient With Type 1 Diabetes. JCEM Case Rep 2024; 2(7): luae102.
  49. Tauschmann M, Thabit H, Bally L, et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet 2018; 392(10155): 1321-9.
  50. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med 2019; 381(18): 1707-17.
  51. Breton MD, Kanapka LG, Beck RW, et al. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. N Engl J Med 2020; 383(9): 836-45.
  52. Burnside MJ, Lewis DM, Crocket HR, et al. Open-Source Automated Insulin Delivery in Type 1 Diabetes. N Engl J Med 2022; 387(10): 869-81.
  53. Bionic Pancreas Research G, Russell SJ, Beck RW, et al. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med 2022; 387(13): 1161-72.
  54. Kueh MTW, Chew NWS, Al-Ozairi E, le Roux CW. The emergence of obesity in type 1 diabetes. Int J Obes (Lond) 2024; 48(3): 289-301.
  55. Donga E, Dekkers OM, Corssmit EP, Romijn JA. Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol 2015; 173(1): 101-9.
  56. McNally B, Rush A, Spritzler F, Roberts C, Koutnik AP. Therapeutic Carbohydrate Reduction in Type 1 Diabetes. In: Nutrition IfPT, editor.; 2024. p. 96.
  57. KOUTNIK AP, WOOD T, STOROSCHUK K, LENNERZ BS. 608-P: Carbohydrate Intake, Glycemic Control, and Cardiometabolic Risk Factors in Type 1 Diabetes—A Systematic Review and Meta-regression. Diabetes 2024; 73(Supplement_1).

Related topics